Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn Sells 6,865 Shares

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 6,865 shares of Twist Bioscience stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $296,636.65. Following the completion of the transaction, the chief operating officer now owns 161,744 shares in the company, valued at approximately $6,988,958.24. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Monday, August 5th, Patrick John Finn sold 2,885 shares of Twist Bioscience stock. The stock was sold at an average price of $39.93, for a total value of $115,198.05.
• On Tuesday, July 23rd, Patrick John Finn sold 2,207 shares of Twist Bioscience stock. The stock was sold at an average price of $56.62, for a total transaction of $124,960.34.

Twist Bioscience Trading Up 1.3 %

Shares of NASDAQ:TWST opened at $43.34 on Friday. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $60.90. The business has a fifty day simple moving average of $44.94 and a 200 day simple moving average of $43.63. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -12.90 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business’s revenue was up 27.7% compared to the same quarter last year. During the same quarter last year, the business earned ($1.01) EPS. On average, sell-side analysts forecast that Twist Bioscience Co. will post -3.13 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TWST. Point72 Asset Management L.P. lifted its position in Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after buying an additional 613,057 shares in the last quarter. Fred Alger Management LLC raised its stake in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after acquiring an additional 575,080 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after purchasing an additional 300,891 shares in the last quarter. Farallon Capital Management LLC bought a new stake in shares of Twist Bioscience during the second quarter valued at approximately $9,462,000. Finally, Driehaus Capital Management LLC increased its holdings in shares of Twist Bioscience by 63.0% in the second quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock valued at $19,152,000 after purchasing an additional 150,260 shares in the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the subject of several recent research reports. TD Cowen increased their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Robert W. Baird raised their price objective on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Barclays lowered their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Finally, Evercore ISI lifted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.63.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.